Impairments and Other Charges |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring and Related Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
| Impairments and Other Charges | Impairments and Other Charges The following table presents various pre-tax charges we recorded during the years ended December 31, 2025 and 2024, which are reflected within “Impairments and other charges” on our Consolidated Statements of Operations.
impairment of assets held for sale related to our chemical business, fixed and other asset write-offs of $115 million, a $53 million impairment associated with facility closures and lease terminations, $50 million equity in earnings loss, and $106 million of other charges, primarily related to legacy environmental remediation cost estimate increases. Offsetting these charges were a release of accruals related to a cybersecurity incident from the third quarter of 2024 for $10 million and a gain of $6 million related to an equity investment. For the year ended December 31, 2024, the charges included $63 million of severance costs, a $49 million impairment of assets held for sale, $35 million in expenses related to a cybersecurity incident, and $12 million of other charges, and were partially offset by a $43 million gain related to a fair value adjustment on an equity investment. For the year ended December 31, 2023, there were no amounts recorded in impairment and other charges. |
||||||||||||||||||||||||||||||||||||||||||||||||